Study Summary
This is a clinical trial of Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the treatment of patients with relapsed / refractory acute myeloid leukemia. The purpose is to evaluate the safety and efficacy of anti-FLT3 CAR-T cells in patients with relapsed / refractory acute myeloid leukemia.
Want to learn more about this trial?
Request More InfoInterventions
Fludarabine + Cyclophosphamide + TAA05 Cell InjectionDRUG
Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Wuhan Union Hospital | Wuhan | Hubei | China |